Annual report
2590.TEDINET S100XYDT
Period2025-01-21 → 2026-01-20
Filed2026-04-14
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 148
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥241.2bn | 2025-01-21 → 2026-01-20 | Cons. | Net sales |
| Revenue | ¥237.2bn | 2024-01-21 → 2025-01-20 | Cons. | Net sales |
| Revenue | ¥213.4bn | 2023-01-21 → 2024-01-20v | Cons. | Net sales (5-year summary) |
| Revenue | ¥160.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net sales (5-year summary) |
| Revenue | ¥162.6bn | 2021-01-21 → 2022-01-20d | Cons. | Net sales (5-year summary) |
| Operating income | ¥4.2bn | 2025-01-21 → 2026-01-20 | Cons. | Operating income |
| Operating income | ¥4.8bn | 2024-01-21 → 2025-01-20 | Cons. | Operating income |
| Ordinary income | ¥1.5bn | 2025-01-21 → 2026-01-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.0bn | 2024-01-21 → 2025-01-20 | Cons. | Ordinary income |
| Ordinary income | ¥3.1bn | 2023-01-21 → 2024-01-20v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥591m | 2022-01-21 → 2023-01-20v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.7bn | 2021-01-21 → 2022-01-20d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | −¥27.8bn | 2025-01-21 → 2026-01-20 | Cons. | Income before income taxes |
| Profit before tax | ¥7.9bn | 2024-01-21 → 2025-01-20 | Cons. | Income before income taxes |
| Net income (owners) | −¥30.3bn | 2025-01-21 → 2026-01-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥3.8bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥4.4bn | 2023-01-21 → 2024-01-20v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥507m | 2022-01-21 → 2023-01-20v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥4.0bn | 2021-01-21 → 2022-01-20d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | −¥31.3bn | 2025-01-21 → 2026-01-20 | Cons. | Profit loss |
| Net income | ¥3.4bn | 2024-01-21 → 2025-01-20 | Cons. | Profit loss |
| Total assets | ¥162.8bn | at 2026-01-20 | Cons. | Assets |
| Total assets | ¥185.2bn | at 2025-01-20 | Cons. | Assets |
| Total assets | ¥177.6bn | at 2024-01-20v | Cons. | Total assets (5-year summary) |
| Total assets | ¥164.2bn | at 2023-01-20v | Cons. | Total assets (5-year summary) |
| Total assets | ¥159.0bn | at 2022-01-20d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥97.9bn | at 2026-01-20 | Cons. | Liabilities |
| Total liabilities | ¥91.7bn | at 2025-01-20 | Cons. | Liabilities |
| Net assets / equity | ¥64.9bn | at 2026-01-20 | Cons. | Net assets |
| Net assets / equity | ¥93.5bn | at 2025-01-20 | Cons. | Net assets |
| Net assets / equity | ¥91.5bn | at 2024-01-20v | Cons. | Net assets |
| Net assets / equity | ¥84.1bn | at 2023-01-20v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥83.3bn | at 2022-01-20d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥28.0bn | at 2026-01-20 | Cons. | Cash and deposits |
| Cash and deposits | ¥30.7bn | at 2025-01-20 | Cons. | Cash and deposits |
| Cash & equivalents | ¥27.9bn | at 2026-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.6bn | at 2025-01-20 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥33.7bn | at 2024-01-20v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥29.2bn | at 2023-01-20v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥30.1bn | at 2022-01-20d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥11.4bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥10.8bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥9.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥5.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥8.1bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥12.1bn | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥11.6bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥5.0bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥6.5bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥300m | 2025-01-21 → 2026-01-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥1.7bn | 2024-01-21 → 2025-01-20 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥3.2bn | 2023-01-21 → 2024-01-20v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥1.1bn | 2022-01-21 → 2023-01-20v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥3.7bn | 2021-01-21 → 2022-01-20d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥-957.83 | 2025-01-21 → 2026-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥120.66 | 2024-01-21 → 2025-01-20 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥140.77 | 2023-01-21 → 2024-01-20v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-16.2 | 2022-01-21 → 2023-01-20v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥127.1 | 2021-01-21 → 2022-01-20d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥2,028.83 | at 2026-01-20 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,908.51 | at 2025-01-20 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,843.99 | at 2024-01-20v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,663.79 | at 2023-01-20v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,645.36 | at 2022-01-20d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 39.5% | at 2026-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.6% | at 2025-01-20 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.4% | at 2024-01-20v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 50.9% | at 2023-01-20v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 52.1% | at 2022-01-20d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | -38.8% | 2025-01-21 → 2026-01-20 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.2% | 2024-01-21 → 2025-01-20 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 5.1% | 2023-01-21 → 2024-01-20v | Cons. | Rate of return on equity (5-year summary) |
| ROE | -0.6% | 2022-01-21 → 2023-01-20v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 4.8% | 2021-01-21 → 2022-01-20d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 5,375 | at 2026-01-20 | Cons. | Number of employees |
| Employees | 5,555 | at 2025-01-20 | Cons. | Number of employees |
| Employees | 5,182 | at 2024-01-20v | Cons. | Number of employees |
| Employees | 4,122 | at 2023-01-20v | Cons. | Number of employees |
| Employees | 4,029 | at 2022-01-20d | Cons. | Number of employees |
| Revenue | ¥5.0bn | 2025-01-21 → 2026-01-20 | Standalone | Operating revenue1 |
| Revenue | ¥5.4bn | 2024-01-21 → 2025-01-20 | Standalone | Operating revenue1 |
| Revenue | ¥5.3bn | 2023-01-21 → 2024-01-20v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥5.0bn | 2022-01-21 → 2023-01-20v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥4.8bn | 2021-01-21 → 2022-01-20d | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥831m | 2025-01-21 → 2026-01-20 | Standalone | Operating income |
| Operating income | ¥972m | 2024-01-21 → 2025-01-20 | Standalone | Operating income |
| Ordinary income | ¥938m | 2025-01-21 → 2026-01-20 | Standalone | Ordinary income |
| Ordinary income | ¥1.4bn | 2024-01-21 → 2025-01-20 | Standalone | Ordinary income |
| Ordinary income | ¥2.0bn | 2023-01-21 → 2024-01-20v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.3bn | 2022-01-21 → 2023-01-20v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.4bn | 2021-01-21 → 2022-01-20d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | −¥25.8bn | 2025-01-21 → 2026-01-20 | Standalone | Income before income taxes |
| Profit before tax | ¥4.2bn | 2024-01-21 → 2025-01-20 | Standalone | Income before income taxes |
| Net income | −¥26.1bn | 2025-01-21 → 2026-01-20 | Standalone | Profit loss |
| Net income | ¥3.1bn | 2024-01-21 → 2025-01-20 | Standalone | Profit loss |
| Net income | ¥2.9bn | 2023-01-21 → 2024-01-20v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.9bn | 2022-01-21 → 2023-01-20v | Standalone | Net income loss (5-year summary) |
| Net income | ¥1.4bn | 2021-01-21 → 2022-01-20d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥97.4bn | at 2026-01-20 | Standalone | Assets |
| Total assets | ¥126.0bn | at 2025-01-20 | Standalone | Assets |
| Total assets | ¥124.8bn | at 2024-01-20v | Standalone | Total assets (5-year summary) |
| Total assets | ¥122.7bn | at 2023-01-20v | Standalone | Total assets (5-year summary) |
| Total assets | ¥122.2bn | at 2022-01-20d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥40.6bn | at 2026-01-20 | Standalone | Liabilities |
| Total liabilities | ¥43.3bn | at 2025-01-20 | Standalone | Liabilities |
| Net assets / equity | ¥56.7bn | at 2026-01-20 | Standalone | Net assets |
| Net assets / equity | ¥82.6bn | at 2025-01-20 | Standalone | Net assets |
| Net assets / equity | ¥82.4bn | at 2024-01-20v | Standalone | Net assets |
| Net assets / equity | ¥80.5bn | at 2023-01-20v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥80.1bn | at 2022-01-20d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥15.2bn | at 2026-01-20 | Standalone | Cash and deposits |
| Cash and deposits | ¥21.7bn | at 2025-01-20 | Standalone | Cash and deposits |
| EPS (basic) | ¥-825.36 | 2025-01-21 → 2026-01-20 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥98.35 | 2024-01-21 → 2025-01-20 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥92.22 | 2023-01-21 → 2024-01-20v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥61.07 | 2022-01-21 → 2023-01-20v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥45.88 | 2021-01-21 → 2022-01-20d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥30 | 2025-01-21 → 2026-01-20 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥40 | 2024-01-21 → 2025-01-20 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2023-01-21 → 2024-01-20v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2022-01-21 → 2023-01-20v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥60 | 2021-01-21 → 2022-01-20d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,789.67 | at 2026-01-20 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,614.69 | at 2025-01-20 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,618.07 | at 2024-01-20v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,564.03 | at 2023-01-20v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,559.09 | at 2022-01-20d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 58.3% | at 2026-01-20 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2025-01-20 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 66.0% | at 2024-01-20v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2023-01-20v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 65.6% | at 2022-01-20d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | -37.5% | 2025-01-21 → 2026-01-20 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.8% | 2024-01-21 → 2025-01-20 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 3.6% | 2023-01-21 → 2024-01-20v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 2.4% | 2022-01-21 → 2023-01-20v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 1.8% | 2021-01-21 → 2022-01-20d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 33,137,000 | at 2026-01-20 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 33,137,000 | at 2025-01-20 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2024-01-20v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2023-01-20v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 16,568,000 | at 2022-01-20d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 52 | at 2026-01-20 | Standalone | Number of employees |
| Employees | 51 | at 2025-01-20 | Standalone | Number of employees |
| Employees | 39 | at 2024-01-20v | Standalone | Number of employees |
| Employees | 26 | at 2023-01-20v | Standalone | Number of employees |
| Employees | 23 | at 2022-01-20d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 97
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-01-21 → 2026-01-20 | ¥1.0bn |
| Reconciling Itemsreconciling | depreciation | 2025-01-21 → 2026-01-20 | ¥949m |
| Reconciling Itemsreconciling | revenue | 2025-01-21 → 2026-01-20 | −¥368m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-01-21 → 2026-01-20 | −¥368m |
| Reconciling Itemsreconciling | segment assets | at 2026-01-20 | ¥34.2bn |
| Reconciling Itemsreconciling | segment profit | 2025-01-21 → 2026-01-20 | −¥2.1bn |
| Domestic Beverage Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥6.8bn |
| Domestic Beverage Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥6.0bn |
| Domestic Beverage Businessreportable segment | employees | at 2026-01-20 | 3514 pure |
| Domestic Beverage Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥142.7bn |
| Domestic Beverage Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥142.5bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥119m |
| Domestic Beverage Businessreportable segment | segment assets | at 2026-01-20 | ¥43.9bn |
| Domestic Beverage Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | −¥2.3bn |
| Dy Do Pharmareportable segment | capex | 2025-01-21 → 2026-01-20 | ¥20m |
| Dy Do Pharmareportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥61m |
| Dy Do Pharmareportable segment | employees | at 2026-01-20 | 12 pure |
| Dy Do Pharmareportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥606m |
| Dy Do Pharmareportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥606m |
| Dy Do Pharmareportable segment | segment assets | at 2026-01-20 | ¥892m |
| Dy Do Pharmareportable segment | segment profit | 2025-01-21 → 2026-01-20 | −¥321m |
| Food Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥1.3bn |
| Food Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥878m |
| Food Businessreportable segment | employees | at 2026-01-20 | 295 pure |
| Food Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥19.6bn |
| Food Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥19.6bn |
| Food Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥7m |
| Food Businessreportable segment | segment assets | at 2026-01-20 | ¥20.0bn |
| Food Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥487m |
| International Beverage Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥6.2bn |
| International Beverage Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥2.1bn |
| International Beverage Businessreportable segment | employees | at 2026-01-20 | 1147 pure |
| International Beverage Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥65.3bn |
| International Beverage Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥65.3bn |
| International Beverage Businessreportable segment | segment assets | at 2026-01-20 | ¥47.0bn |
| International Beverage Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥7.5bn |
| Pharmaceutical Related Businessreportable segment | capex | 2025-01-21 → 2026-01-20 | ¥1.5bn |
| Pharmaceutical Related Businessreportable segment | depreciation | 2025-01-21 → 2026-01-20 | ¥1.1bn |
| Pharmaceutical Related Businessreportable segment | employees | at 2026-01-20 | 355 pure |
| Pharmaceutical Related Businessreportable segment | revenue | 2025-01-21 → 2026-01-20 | ¥13.4bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2025-01-21 → 2026-01-20 | ¥13.2bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥241m |
| Pharmaceutical Related Businessreportable segment | segment assets | at 2026-01-20 | ¥16.9bn |
| Pharmaceutical Related Businessreportable segment | segment profit | 2025-01-21 → 2026-01-20 | ¥829m |
| —segment total | capex | 2025-01-21 → 2026-01-20 | ¥16.0bn |
| —segment total | depreciation | 2025-01-21 → 2026-01-20 | ¥10.2bn |
| —segment total | revenue | 2025-01-21 → 2026-01-20 | ¥241.6bn |
| —segment total | revenue external | 2025-01-21 → 2026-01-20 | ¥241.2bn |
| —segment total | revenue intersegment | 2025-01-21 → 2026-01-20 | ¥368m |
| —segment total | segment assets | at 2026-01-20 | ¥128.6bn |
| —segment total | segment profit | 2025-01-21 → 2026-01-20 | ¥6.3bn |
| Reconciling Itemsreconciling | capex | 2024-01-21 → 2025-01-20 | ¥597m |
| Reconciling Itemsreconciling | depreciation | 2024-01-21 → 2025-01-20 | ¥796m |
| Reconciling Itemsreconciling | revenue | 2024-01-21 → 2025-01-20 | −¥378m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-01-21 → 2025-01-20 | −¥378m |
| Reconciling Itemsreconciling | segment assets | at 2025-01-20 | ¥34.5bn |
| Reconciling Itemsreconciling | segment profit | 2024-01-21 → 2025-01-20 | −¥2.1bn |
| Domestic Beverage Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥7.1bn |
| Domestic Beverage Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥5.6bn |
| Domestic Beverage Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥147.5bn |
| Domestic Beverage Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥147.4bn |
| Domestic Beverage Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥86m |
| Domestic Beverage Businessreportable segment | segment assets | at 2025-01-20 | ¥74.8bn |
| Domestic Beverage Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥986m |
| Dy Do Pharmareportable segment | capex | 2024-01-21 → 2025-01-20 | ¥382m |
| Dy Do Pharmareportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥21m |
| Dy Do Pharmareportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥8m |
| Dy Do Pharmareportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥8m |
| Dy Do Pharmareportable segment | segment assets | at 2025-01-20 | ¥780m |
| Dy Do Pharmareportable segment | segment profit | 2024-01-21 → 2025-01-20 | −¥621m |
| Food Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥1.2bn |
| Food Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥834m |
| Food Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥20.7bn |
| Food Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥20.6bn |
| Food Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥7m |
| Food Businessreportable segment | segment assets | at 2025-01-20 | ¥21.0bn |
| Food Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥1.2bn |
| International Beverage Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥9.0bn |
| International Beverage Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥1.9bn |
| International Beverage Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥56.3bn |
| International Beverage Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥56.3bn |
| International Beverage Businessreportable segment | segment assets | at 2025-01-20 | ¥37.5bn |
| International Beverage Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥5.1bn |
| Pharmaceutical Related Businessreportable segment | capex | 2024-01-21 → 2025-01-20 | ¥576m |
| Pharmaceutical Related Businessreportable segment | depreciation | 2024-01-21 → 2025-01-20 | ¥1.4bn |
| Pharmaceutical Related Businessreportable segment | revenue | 2024-01-21 → 2025-01-20 | ¥13.1bn |
| Pharmaceutical Related Businessreportable segment | revenue external | 2024-01-21 → 2025-01-20 | ¥12.8bn |
| Pharmaceutical Related Businessreportable segment | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥284m |
| Pharmaceutical Related Businessreportable segment | segment assets | at 2025-01-20 | ¥16.6bn |
| Pharmaceutical Related Businessreportable segment | segment profit | 2024-01-21 → 2025-01-20 | ¥277m |
| —segment total | capex | 2024-01-21 → 2025-01-20 | ¥18.2bn |
| —segment total | depreciation | 2024-01-21 → 2025-01-20 | ¥9.7bn |
| —segment total | revenue | 2024-01-21 → 2025-01-20 | ¥237.6bn |
| —segment total | revenue external | 2024-01-21 → 2025-01-20 | ¥237.2bn |
| —segment total | revenue intersegment | 2024-01-21 → 2025-01-20 | ¥378m |
| —segment total | segment assets | at 2025-01-20 | ¥150.8bn |
| —segment total | segment profit | 2024-01-21 → 2025-01-20 | ¥6.9bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,846
| Item | Context | Value | Unit |
|---|---|---|---|
| Net assets | CurrentYearInstant_NonConsolidatedMember | 56733000000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第1項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)近畿財務局長 | |
| Filing date cover page | FilingDateInstant | 2026-04-14 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第51期（自 2025年1月21日 至 2026年1月20日） | |
| Company name cover page | FilingDateInstant | Original text (Japanese)ダイドーグループホールディングス株式会社 | |
| Company name in english cover page | FilingDateInstant | DyDo GROUP HOLDINGS,INC. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 髙松 富也 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)大阪市北区中之島二丁目2番7号 | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | 06（7166）0011 | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)取締役執行役員財務部長 殿勝 直樹 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)大阪市北区中之島二丁目2番7号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 06（6222）2641 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)取締役執行役員財務部長 殿勝 直樹 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E00424 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 25900 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)ダイドーグループホールディングス株式会社 | |
| Filer name in english | FilingDateInstant | DyDo GROUP HOLDINGS,INC. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | CTE | |
| Current fiscal year start date | FilingDateInstant | 2025-01-21 | |
| Current period end date | FilingDateInstant | 2026-01-20 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2026-01-20 | |
| Previous fiscal year start date | FilingDateInstant | 2024-01-21 | |
| Comparative period end date | FilingDateInstant | 2025-01-20 | |
| Previous fiscal year end date | FilingDateInstant | 2025-01-20 | |
| Next fiscal year start date | FilingDateInstant | － | |
| End date of quarterly or semi annual period of next fiscal year | FilingDateInstant | － | |
| Amendment flag | FilingDateInstant | false | |
| Identification of document subject to amendment | FilingDateInstant | － | |
| Report amendment flag | FilingDateInstant | false | |
| Xbrl amendment flag | FilingDateInstant | false | |
| Business results of group (text) | FilingDateInstant | Text · Plus | |
| Business results of reporting company (text) | FilingDateInstant | Text · Plus | |
| Company history (text) | FilingDateInstant | Text · Plus | |
| Description of business (text) | FilingDateInstant | Text · Plus | |
| Overview of affiliated entities (text) | FilingDateInstant | Text · Plus | |
| Information about employees (text) | FilingDateInstant | Text · Plus | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row1Member | Original text (Japanese)ダイドードリンコ㈱ | |
| Consolidated subsidiaries metrics of consolidated subsidiaries | CurrentYearInstant_Row2Member | Original text (Japanese)ダイドーアサヒベンディング㈱ |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |